Skip to main content
. Author manuscript; available in PMC: 2019 Jan 12.
Published in final edited form as: N Engl J Med. 2018 Jun 3;379(2):111–121. doi: 10.1056/NEJMoa1804710

Figure 2. Clinical Outcomes among Patients with a Recurrence Score of 11 to 25.

Figure 2.

Kaplan–Meier estimates of survival rates in the analysis according to the assigned treatment group are shown for the group that received endocrine therapy alone and the group that received chemoendocrine therapy in the intention- to-treat analysis of invasive disease–free survival (defined as freedom from invasive disease recurrence, second primary cancer, or death) and freedom from recurrence of breast cancer at a distant site. The hazard ratios are for the endocrine-therapy group versus the chemoendocrine-therapy group.